Kinetic studies and CFD-based reaction modeling for insights into the scalability of ADC conjugation reactions.
antibody-drug conjugate (ADC)
computational fluid dynamics (CFD)
conjugation reaction
kinetic modeling
mixing
scale-up
single-use
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
12
2022
accepted:
24
03
2023
medline:
21
4
2023
pubmed:
21
4
2023
entrez:
21
04
2023
Statut:
epublish
Résumé
The manufacturing of antibody-drug conjugates (ADCs) involves the addition of a cytotoxic small-molecule linker-drug (= payload) to a solution of functionalized antibodies. For the development of robust conjugation processes, initially small-scale reaction tubes are used which requires a lot of manual handling. Scale-up to larger reaction vessels is often knowledge-driven and scale-comparability is solely assessed based on final product quality which does not account for the dynamics of the reaction. In addition, information about the influence of process parameters, such as stirrer speed, temperature, or payload addition rates, is limited due to high material costs. Given these limitations, there is a need for a modeling-based approach to investigate conjugation scale-up. In this work, both experimental kinetic studies and computational fluid dynamics (CFD) conjugation simulations were performed to understand the influence of scale and mixing parameters. In the experimental part, conjugation kinetics in small-scale reaction tubes with different mixing types were investigated for two ADC systems and compared to larger bench-scale reactions. It was demonstrated that more robust kinetics can be achieved through internal stirrer mixing instead of external mixing devices, such as orbital shakers. In the simulation part, 3D-reactor models were created by coupling CFD-models for three large-scale reaction vessels with a kinetic model for a site-specific conjugation reaction. This enabled to study the kinetics in different vessels, as well as the effect of process parameter variations
Identifiants
pubmed: 37082211
doi: 10.3389/fbioe.2023.1123842
pii: 1123842
pmc: PMC10111256
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1123842Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Weggen, Seidel, Bean, Wendeler and Hubbuch.
Déclaration de conflit d'intérêts
Authors MW and RB are employed by AstraZeneca PLC. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Biotechnol. 2019 Dec 20;306:71-80
pubmed: 31557498
Biotechnol Adv. 2021 Jan-Feb;46:107660
pubmed: 33221379
Biotechnol Bioeng. 2019 Apr;116(4):769-780
pubmed: 30450609
Protein Cell. 2018 Jan;9(1):33-46
pubmed: 27743348
Biotechnol Prog. 2018 Sep;34(5):1120-1128
pubmed: 30281943
Bioconjug Chem. 2020 Sep 16;31(9):2136-2146
pubmed: 32697078
Adv Biochem Eng Biotechnol. 2021;176:1-34
pubmed: 33349908
MAbs. 2021 Jan-Dec;13(1):1951427
pubmed: 34291723
Trends Biotechnol. 2019 Jul;37(7):697-706
pubmed: 30737008
Biotechnol Bioeng. 2022 Feb;119(2):523-534
pubmed: 34741535
Trends Biotechnol. 2020 Oct;38(10):1141-1153
pubmed: 32518043
Biotechnol Bioeng. 2020 Dec;117(12):3986-4000
pubmed: 32725887
MAbs. 2014 Jan-Feb;6(1):34-45
pubmed: 24423619
Adv Biochem Eng Biotechnol. 2021;176:71-96
pubmed: 33346864
Biotechnol Bioeng. 2020 Jun;117(6):1710-1723
pubmed: 32159221
MAbs. 2019 Aug/Sep;11(6):1064-1076
pubmed: 31198090
Methods Mol Biol. 2013;1045:235-48
pubmed: 23913151
Biotechnol Bioeng. 2020 Nov;117(11):3400-3412
pubmed: 32672835
Expert Opin Biol Ther. 2021 Jul;21(7):963-975
pubmed: 33141625